Darnitsa is Ready to Ensure the Manufacturing of Drugs for Intensive Care

Darnitsa Pharmaceutical Company informs of the availability of medicinal products in stock for use in the intensive care for 2 to 4 months.

This refers to medications that may be used for treatment of patients in serious and critical conditions with SARS-CoV-2. Patients with COVID-19 connected to lung ventilators and staying in a serious condition in intensive care units may require up to 50 various medicinal products.

In view of the increase in the number of those infected in the EU countries, the European Commission seriously rates the threat of shortage of medications for treatment of patients with COVID-19.

Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group:

“Ukraine should have a strategic reserve of medications. This refers to sedative, anesthetic agents, drugs for resuscitation, muscle relaxants and antibiotics. Darnitsa’s product portfolio includes a considerable part of medicinal products which may be used in case of medical emergencies in patients with COVID-19. We assess that their stocks will last for 2 to 4 months. We also build up the stocks of raw materials to ensure their manufacturing according to the needs of the healthcare system.”

Darnitsa’s product portfolio includes a considerable part of medicinal products which may be used in case of medical emergencies in patients with COVID-19 and included to the list of medicinal products, medical devices and equipment intended for prevention of the development and spreading of the coronavirus disease Covid-19, as approved by the Cabinet of Ministers in March.

Darnitsa also manufactures other medicinal products, which are not on the list approved by the Cabinet of Ministers, but may be necessary in case of medical emergencies.

The European Commission seriously rates the threat of shortage of medications for treatment of patients with COVID-19 in view of the increase in the number of those infected in the EU countries.

Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group:

“This refers to sedative, anesthetic agents, drugs for resuscitation, muscle relaxants and antibiotics. Darnitsa’s product portfolio includes 6 molecules used in case of medical emergencies in patients with COVID-19 as part of intensive care. We build up the stocks of raw materials to ensure the manufacturing of such drugs.”

Darnitsa’s product portfolio includes 6 molecules used in case of medical emergencies in patients with COVID-19 as part of intensive care. Medical products based on such molecules are on the “List of medicinal products, medical devices and/or equipment necessary for carrying out measures aimed at the prevention of the development and spreading, localization and liquidation of outbreaks, epidemics and pandemics of the coronavirus disease (COVID-19), which are exempt from the import duty and operations of importation of which to the customs territory of Ukraine are exempt from the value added tax”, as approved by the Resolution of the Cabinet of Ministers of Ukraine No. 224 dated March 20, 2020.

Darnitsa also manufactures other molecules which are not on the list approved by the Cabinet of Ministers, but may be necessary in case of medical emergencies.